Online son
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Everyone start emailing him
Heartbeat today.
We green baby
Back at .0001 on Friday
Today's the day. News. Wahooo
Deal with Apple. Apple watch uses these parts
Stock rock bottom no news in years
He's in the depths of the lo
Fish ain't flopin anymore
No pulse just G5 jets
Chris you mother Flower D SHAPER make a move
Boom. It's bout that time baby. Sitting on a pile of 0001 like a donkey loves rain
Today's the news day.
TGGI has been able to negotiate and eliminate $82,740.61 in accrued interest and $373,043 of long-term convertible debt on its books as of 12/31/14. The only remaining convertible debt on the books of TGGI is $56,000 and NO interest will accrue on that debt. The reductions were made without the issuance of additional shares of the company's common stock or its preferred stock. The Company did exchange 100% of its ownership in its subsidiary company f/k/a Rollings.Com for $101,526.96 debt cancellation. Chris Clarke, the Company's CEO states "When I became CEO in 2012, the long-term debt was over $750,000 and because of interest accruing, the long-term debt and interest total grew to over $980,000 by 2013. It has taken me three years, but I have finally ended this toxic debt issue and the Company's long-term debt stands at $56,000 with NO interest accruing."
Trans Global Group, Inc. and International Green Building Group, Inc. have mutually agreed and executed a rescission agreement to rescind their Securities Exchange Agreement executed in June of 2014. TGGI CEO states "I felt it was best for the Company to part ways with International Green Building Group, Inc. due to differences in business focus moving forward. I would like to wish Nathan Hall and his Companies the best of luck." Mr. Clarke further states "I am in final negotiations with a Construction Development Company that I feel will provide TGGI shareholders added value moving forward."
TGGI in compliance with SEC regulations may use social media outlets like Facebook or Twitter to announce key information in compliance with Regulation Fair Disclosure. The Company's Facebook page is: https://www.facebook.com/TransGlobalGroupInc. Look for Company updates on Facebook in the near future.
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "believes", "expects", "potential", "plans", "suggests", "may", "should", "could", "intends", or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
The silence before the nail in the coffin
This stock will never tick again.
What in the flying f is going on with this stock. Come on people ain't got forever to get rich.
Let the dump begin
He is
We will touch .001 this year. And I'll be here when we do. Wahooo
It's only blind if flowers had rugs!
Friday dump
Today we launch !!!!!
I believe in magic
Wahoooo news might be coming
Great week ahead
THIS IS THE WEEK!!
PharmaCom BioVet, Inc. is in the business of providing integrated animal healthcare services utilizing veterinary oncology, or the study and treatment of cancer in companion animals. In the United States alone, it is estimated that companion animal caregivers spend in excess of $52 billion annually on overall companion animal care. It is also estimated that over $17 billion annually (2006) is spent on veterinary care. PharmaCom BioVet has developed a comprehensive business plan to accelerate product research and development. Additionally, the company intends to introduce a series of proprietary devices and compounds that will enable animals suffering form cancer greater life expectancy and decreased suffering.
Your browser may not support display of this image.
PHARMACOM BIOVET, INC.
(PHMB.PK)
BUSINESS STRATEGY
PharmaCom BioVet is committed to increasing shareholder value, aggressively pursuing strategic alliances that can add immediately to the product line.
Securing funding to properly manage the company’s planned growth
Implementing comprehensive marketing plans and realistic revenue projections
Capitalizing on the growing veterinary market, as there have been few other viable cancer therapeutic products introduced into the veterinary marketplace over the past 30 years
Expanding the number of affiliated sites to increase its revenue base and help meet operating expenses
As animal lovers, there is nothing you wouldn’t do for your pet. Cancer in pets has been on the rise the past few years. For dogs over six years of age, 60 percent will be diagnosed with some form of cancer. Nearly half the deaths of pets more than 10 years old are from cancer. There are nearly 100 types of animal cancer. The most common type is leukemia, and the most common cancer for dogs is lymphoma and mammary gland cancer. Because of treatment advances PharmaCom BioVet offers, pets with cancer have a much better chance of survival then they did just a few short years ago.
PHMB remains dedicated to advancing the medical care industry for companion animals by establishing state-of-the-art treatment centers for lymphoma and other forms of cancer throughout the United States and beyond. The company has a top-notch, highly skilled and well-respected management team leading its Board of Directors and operations division.
FUTURE PLANS
PharmaCom BioVet has begun to establish facilities for the treatment and further development of Veterinary Oncology Canine Cancer Treatment Centers in Missouri, Texas and Connecticut. The expansion of these sites should allow the company to provide more comprehensive services, thereby increasing the revenue earned from each. The expansion of owned and affiliated sites will create further market outlets for the company’s treatment services and allow greater market capture of the underlying populations requiring those services. The expanded network will be positioned to capture canine heath services as a managed care disease-specific provider, providing larger economies of scale, allowing more clinical data for medical and financial analysis, and likely, allowing PHMB to conduct larger clinical trials of its Bone Marrow Transplant technique. Of note, there are in excess of over 10,000 dogs annually in the U. S. receiving chemotherapy for lymphoma cancer alone, with a life expectancy, of up to 1 year, on average.
These are the target patients of PharmaCom BioVet, Inc. Through this treatment, the company hopes to improve the prognosis for life expectancy --- 3 to 5 times longer from what is currently being seen.
INVESTMENT CONSIDERATIONS
There are exciting and challenging opportunities in areas of bone marrow transplant and other cancer treatment technologies for companion animals. Products developed by bright and enterprising engineers, medical professionals and others, are ready for the final stages of registration. PharmaCom BioVet, Inc. is well positioned to use its capital and management skills to evaluate new ventures, as well as implement plans for current ventures, and operate its new centers to achieve sales and revenue growth. At this current level, PHMB represents a most compelling investment opportunity for those investors who aggressively seek the potential of maximum long-term capital gains in a dynamically growing entity. The company is now poised for dramatic and profitable growth. It is PHMB’s objective to capitalize on the relationships and partnerships with some of the top Veterinary Oncologists and Veterinary Researchers in the U.S. to enable management to bring revolutionary new treatment procedures to the companion animal healthcare market.
Management states, “The development and commercial availability of a new veterinary-specific cancer treatment suggests the potential for high profitability, based upon known and projected demand. These profits would not only support a strong revenue stream for PharmaCom BioVet, Inc.’s operations, but would also allow for the ongoing development of further products and/or treatment techniques.”
ANALYST
Officers of Market Advisors, Inc. have been in business since 1983 and have provided stock market research for their clients since 1985. Company officials have often been quoted in a wide array of financial publications such as the Wall Street Journal, Investors Business Daily, Barron’s, Forbes Magazine and The Dick Davis Digest to name a few.
Trans Global Projects has expanded its presence in Europe with the acquisition of a leading Swiss logistics firm.
Project specialist NATCO AG has been operating in Switzerland for more than 35 years, successfully positioning itself as an exclusive, high quality service provider in the industrial projects and heavy lift sector. Air freight is a further specialisation of the company, while road and sea cargo services are also provided. Offering a similar range of services as Trans Global Projects does on an international platform, the two companies have a common multi-national customer base, enabling the merged firm to offer an enhanced service to clients.
NATCO’s devotion to providing a high standard of service, combined with its central European location in Switzerland, made the company an excellent choice as Trans Global Projects’ first major acquisition.
A significant step in the group’s continued development, the multi-million pound deal completes on 1 January 2015.
NATCO AG will continue to operate as usual, with re-branding proposed later in the year. See www.natco.ch to find out more about the organisation.
For further information or to discuss your own company's project logistics requirements, contact the central Commercial Department at commercial@tglobal.com or phone +44 1732 744 400 or NATCO AG at commercial@natco.ch or phone +41 44 818 7920.
MOST DEAD STOCK ON THE MARKET. WOW.
Junk. ??????
Baby gonna fly next 30days.
Wahoooo news today. I feel it
Wahooooooo. Super vol.
NEWS. WAHOOOOO
can't wait
What's the deal.
Why the 00
Go baby go
Wake up. Great day ahead of us.